[Vaccination in adult rheumatology].
Identifieur interne : 000456 ( Main/Exploration ); précédent : 000455; suivant : 000457[Vaccination in adult rheumatology].
Auteurs : A. Rubbert-Roth [Allemagne]Source :
- Zeitschrift fur Rheumatologie [ 0340-1855 ] ; 2007.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Allemagne (MeSH), Grippe humaine (induit chimiquement), Grippe humaine (prévention et contrôle), Guides de bonnes pratiques cliniques comme sujet (MeSH), Humains (MeSH), Immunosuppresseurs (effets indésirables), Immunosuppresseurs (usage thérapeutique), Infections à pneumocoques (induit chimiquement), Infections à pneumocoques (prévention et contrôle), Rhumatismes (complications), Rhumatismes (traitement médicamenteux), Rhumatologie (méthodes), Rhumatologie (tendances), Types de pratiques des médecins (MeSH), Vaccination (méthodes), Vaccination (tendances).
- MESH :
- effets indésirables : Immunosuppresseurs, Rhumatismes.
- induit chimiquement : Grippe humaine, Infections à pneumocoques.
- méthodes : Rhumatologie, Vaccination.
- prévention et contrôle : Grippe humaine, Infections à pneumocoques.
- tendances : Rhumatologie, Vaccination.
- traitement médicamenteux : Rhumatismes.
- usage thérapeutique : Immunosuppresseurs.
- Adulte, Allemagne, Guides de bonnes pratiques cliniques comme sujet, Humains, Types de pratiques des médecins.
- Wicri :
- geographic : Allemagne.
English descriptors
- KwdEn :
- Adult (MeSH), Germany (MeSH), Humans (MeSH), Immunosuppressive Agents (adverse effects), Immunosuppressive Agents (therapeutic use), Influenza, Human (chemically induced), Influenza, Human (prevention & control), Pneumococcal Infections (chemically induced), Pneumococcal Infections (prevention & control), Practice Guidelines as Topic (MeSH), Practice Patterns, Physicians' (MeSH), Rheumatic Diseases (complications), Rheumatic Diseases (drug therapy), Rheumatology (methods), Rheumatology (trends), Vaccination (methods), Vaccination (trends).
- MESH :
- chemical , adverse effects : Immunosuppressive Agents.
- chemical , therapeutic use : Immunosuppressive Agents.
- geographic : Germany.
- chemically induced : Influenza, Human, Pneumococcal Infections.
- complications : Rheumatic Diseases.
- drug therapy : Rheumatic Diseases.
- methods : Rheumatology, Vaccination.
- prevention & control : Influenza, Human, Pneumococcal Infections.
- trends : Rheumatology, Vaccination.
- Adult, Humans, Practice Guidelines as Topic, Practice Patterns, Physicians'.
Abstract
Patients with rheumatic diseases who are undergoing immunosuppressive therapy have a substantially increased risk of infection compared to the normal population, and are thus candidates for preventive measures. In accordance with the recommendations of the Standing Vaccination Commission of the Robert Koch Institute (Ständigen Impfkommission, STIKO), these individuals, in analogy with other patients with chronic diseases, belong to a risk group for which vaccination against pneumococci and influenza is recommended. Published studies indicate that a limited immune response is possible for patients undergoing immunosuppressive therapy. Here, methotrexate in particular appears to interfere with the success of vaccination against pneumococci. However, a limited immune response against influenza antigens was observed under immunosuppression with mycophenolate mufti, cyclosporine und azathioprine. Consideration must be given to the fact that a patient under continual immunosuppression has a reduced duration of protective immune response. New studies on tumor necrosis factor (TNF) inhibitors indicate that there should be no interference with pneumococcus infection. The possibly variable vaccination success of patients undergoing TNF inhibitor treatment is qualified by the fact that all published results show that the expected immune response after an influenza vaccination is very good. Vaccination strategies in cases in which the use of rituximab and abatacept is planned are currently unclear.
DOI: 10.1007/s00393-007-0144-x
PubMed: 17294061
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Vaccination in adult rheumatology].</title><author><name sortKey="Rubbert Roth, A" sort="Rubbert Roth, A" uniqKey="Rubbert Roth A" first="A" last="Rubbert-Roth">A. Rubbert-Roth</name><affiliation wicri:level="1"><nlm:affiliation>Medizinische Klinik I, Universitätsklinik Köln, Joseph-Stelzmann-Strasse 9, 50924 Köln. andrea.rubbert@uk-koeln.de</nlm:affiliation><country wicri:rule="url">Allemagne</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17294061</idno><idno type="pmid">17294061</idno><idno type="doi">10.1007/s00393-007-0144-x</idno><idno type="wicri:Area/Main/Corpus">000481</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000481</idno><idno type="wicri:Area/Main/Curation">000481</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000481</idno><idno type="wicri:Area/Main/Exploration">000481</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Vaccination in adult rheumatology].</title><author><name sortKey="Rubbert Roth, A" sort="Rubbert Roth, A" uniqKey="Rubbert Roth A" first="A" last="Rubbert-Roth">A. Rubbert-Roth</name><affiliation wicri:level="1"><nlm:affiliation>Medizinische Klinik I, Universitätsklinik Köln, Joseph-Stelzmann-Strasse 9, 50924 Köln. andrea.rubbert@uk-koeln.de</nlm:affiliation><country wicri:rule="url">Allemagne</country></affiliation></author></analytic><series><title level="j">Zeitschrift fur Rheumatologie</title><idno type="ISSN">0340-1855</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Germany (MeSH)</term><term>Humans (MeSH)</term><term>Immunosuppressive Agents (adverse effects)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Influenza, Human (chemically induced)</term><term>Influenza, Human (prevention & control)</term><term>Pneumococcal Infections (chemically induced)</term><term>Pneumococcal Infections (prevention & control)</term><term>Practice Guidelines as Topic (MeSH)</term><term>Practice Patterns, Physicians' (MeSH)</term><term>Rheumatic Diseases (complications)</term><term>Rheumatic Diseases (drug therapy)</term><term>Rheumatology (methods)</term><term>Rheumatology (trends)</term><term>Vaccination (methods)</term><term>Vaccination (trends)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Allemagne (MeSH)</term><term>Grippe humaine (induit chimiquement)</term><term>Grippe humaine (prévention et contrôle)</term><term>Guides de bonnes pratiques cliniques comme sujet (MeSH)</term><term>Humains (MeSH)</term><term>Immunosuppresseurs (effets indésirables)</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Infections à pneumocoques (induit chimiquement)</term><term>Infections à pneumocoques (prévention et contrôle)</term><term>Rhumatismes (complications)</term><term>Rhumatismes (traitement médicamenteux)</term><term>Rhumatologie (méthodes)</term><term>Rhumatologie (tendances)</term><term>Types de pratiques des médecins (MeSH)</term><term>Vaccination (méthodes)</term><term>Vaccination (tendances)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Germany</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Influenza, Human</term><term>Pneumococcal Infections</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Rheumatic Diseases</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Rheumatic Diseases</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Immunosuppresseurs</term><term>Rhumatismes</term></keywords><keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr"><term>Grippe humaine</term><term>Infections à pneumocoques</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Rheumatology</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Rhumatologie</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term><term>Pneumococcal Infections</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term><term>Infections à pneumocoques</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Rhumatologie</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Rhumatismes</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Rheumatology</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Immunosuppresseurs</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Humans</term><term>Practice Guidelines as Topic</term><term>Practice Patterns, Physicians'</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Allemagne</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Types de pratiques des médecins</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients with rheumatic diseases who are undergoing immunosuppressive therapy have a substantially increased risk of infection compared to the normal population, and are thus candidates for preventive measures. In accordance with the recommendations of the Standing Vaccination Commission of the Robert Koch Institute (Ständigen Impfkommission, STIKO), these individuals, in analogy with other patients with chronic diseases, belong to a risk group for which vaccination against pneumococci and influenza is recommended. Published studies indicate that a limited immune response is possible for patients undergoing immunosuppressive therapy. Here, methotrexate in particular appears to interfere with the success of vaccination against pneumococci. However, a limited immune response against influenza antigens was observed under immunosuppression with mycophenolate mufti, cyclosporine und azathioprine. Consideration must be given to the fact that a patient under continual immunosuppression has a reduced duration of protective immune response. New studies on tumor necrosis factor (TNF) inhibitors indicate that there should be no interference with pneumococcus infection. The possibly variable vaccination success of patients undergoing TNF inhibitor treatment is qualified by the fact that all published results show that the expected immune response after an influenza vaccination is very good. Vaccination strategies in cases in which the use of rituximab and abatacept is planned are currently unclear.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17294061</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0340-1855</ISSN><JournalIssue CitedMedium="Print"><Volume>66</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Zeitschrift fur Rheumatologie</Title><ISOAbbreviation>Z Rheumatol</ISOAbbreviation></Journal><ArticleTitle>[Vaccination in adult rheumatology].</ArticleTitle><Pagination><MedlinePgn>102-4, 106-10</MedlinePgn></Pagination><Abstract><AbstractText>Patients with rheumatic diseases who are undergoing immunosuppressive therapy have a substantially increased risk of infection compared to the normal population, and are thus candidates for preventive measures. In accordance with the recommendations of the Standing Vaccination Commission of the Robert Koch Institute (Ständigen Impfkommission, STIKO), these individuals, in analogy with other patients with chronic diseases, belong to a risk group for which vaccination against pneumococci and influenza is recommended. Published studies indicate that a limited immune response is possible for patients undergoing immunosuppressive therapy. Here, methotrexate in particular appears to interfere with the success of vaccination against pneumococci. However, a limited immune response against influenza antigens was observed under immunosuppression with mycophenolate mufti, cyclosporine und azathioprine. Consideration must be given to the fact that a patient under continual immunosuppression has a reduced duration of protective immune response. New studies on tumor necrosis factor (TNF) inhibitors indicate that there should be no interference with pneumococcus infection. The possibly variable vaccination success of patients undergoing TNF inhibitor treatment is qualified by the fact that all published results show that the expected immune response after an influenza vaccination is very good. Vaccination strategies in cases in which the use of rituximab and abatacept is planned are currently unclear.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rubbert-Roth</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medizinische Klinik I, Universitätsklinik Köln, Joseph-Stelzmann-Strasse 9, 50924 Köln. andrea.rubbert@uk-koeln.de</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Impfungen in der Erwachsenenrheumatologie.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Z Rheumatol</MedlineTA><NlmUniqueID>0414162</NlmUniqueID><ISSNLinking>0340-1855</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011008" MajorTopicYN="N">Pneumococcal Infections</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="N">Rheumatic Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012219" MajorTopicYN="N">Rheumatology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>28</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17294061</ArticleId><ArticleId IdType="doi">10.1007/s00393-007-0144-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blood. 2002 Sep 15;100(6):2257-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12200395</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatology (Oxford). 2007 Apr;46(4):608-11</Citation><ArticleIdList><ArticleId IdType="pubmed">17114801</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2002 Jan 15;34(2):147-53</Citation><ArticleIdList><ArticleId IdType="pubmed">11740700</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2006 May;54(5):1390-400</Citation><ArticleIdList><ArticleId IdType="pubmed">16649186</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 2005 Aug;32(8):1473-80</Citation><ArticleIdList><ArticleId IdType="pubmed">16078322</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 2000 Jul;27(7):1681-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10914851</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulster Med J. 2002 Nov;71(2):101-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12513005</ArticleId></ArticleIdList></Reference><Reference><Citation>Transplantation. 2000 Feb 15;69(3):436-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10706057</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2003 Jun;9(6):736-43</Citation><ArticleIdList><ArticleId IdType="pubmed">12740573</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2003 Nov;48(11):3013-22</Citation><ArticleIdList><ArticleId IdType="pubmed">14613261</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2006 Feb;65(2):184-90</Citation><ArticleIdList><ArticleId IdType="pubmed">15975972</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 2004 Jul;31(7):1356-61</Citation><ArticleIdList><ArticleId IdType="pubmed">15229957</ArticleId></ArticleIdList></Reference><Reference><Citation>Respir Med. 2004 Dec;98(12):1187-94</Citation><ArticleIdList><ArticleId IdType="pubmed">15588039</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2006 Feb;65(2):191-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16014674</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 1979 Dec;22(12):1321-5</Citation><ArticleIdList><ArticleId IdType="pubmed">42410</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Rheumatol. 2002 Sep;21(5):369-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12223983</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatology (Oxford). 2006 Jan;45(1):9-10</Citation><ArticleIdList><ArticleId IdType="pubmed">16361703</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2006 Feb;54(2):515-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16447226</ArticleId></ArticleIdList></Reference><Reference><Citation>Autoimmunity. 2005 Nov;38(7):493-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16373254</ArticleId></ArticleIdList></Reference><Reference><Citation>Transplantation. 1998 Nov 27;66(10):1340-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9846520</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2002 Sep;46(9):2287-93</Citation><ArticleIdList><ArticleId IdType="pubmed">12355475</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2005 Oct 26;294(16):2043-51</Citation><ArticleIdList><ArticleId IdType="pubmed">16249418</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatology (Oxford). 2006 Jul;45(7):912-3</Citation><ArticleIdList><ArticleId IdType="pubmed">16638800</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1995 Oct 1;123(7):518-27</Citation><ArticleIdList><ArticleId IdType="pubmed">7661497</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Transplant. 2004 Dec;14(4):346-51</Citation><ArticleIdList><ArticleId IdType="pubmed">15663020</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country></list><tree><country name="Allemagne"><noRegion><name sortKey="Rubbert Roth, A" sort="Rubbert Roth, A" uniqKey="Rubbert Roth A" first="A" last="Rubbert-Roth">A. Rubbert-Roth</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000456 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000456 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeAllemagneV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:17294061
|texte= [Vaccination in adult rheumatology].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:17294061" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV4
| This area was generated with Dilib version V0.6.35. |  |